abstract |
The present invention relates to all stereoisomeric forms, including compounds of formula (I), or pharmaceutically active salts thereof, individual diastereomers and enantiomers thereof, and racemic and non-racemic mixtures thereof. The compounds of the present invention have been found to be highly potent NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD): (I) Where Ar 1 is aryl or heteroaryl; Ar 2 is aryl or heteroaryl; R 1 is hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, S-lower alkyl, -S (O) 2 -lower alkyl, -S (O) 2 -di-lower alkyl amino, cyano, amino, mono or di-lower alkyl amino, C (O) -lower alkyl, NHC (O) -lower alkyl, cycloalkyl, heterocyclyl, or optionally lower alkyl Heteroaryl substituted with; R 2 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted with halogen or cyano; R 3 is hydrogen, halogen, lower alkyl or lower alkyl substituted with halogen; n is 1, 2 or 3; when n is 2 or 3, R 1 may be the same or different; o is 1, 2 or 3; when o is 2 or 3, R 2 may be the same or different; p is 1, 2 or 3; When p is 2 or 3, R 4 may be the same or different. |